# Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

> **NCT06868732** · PHASE1 · RECRUITING · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 288 (estimated)

## Conditions studied

- Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** JSKN016
- **DRUG:** Carboplatin
- **DRUG:** Furmonertinib Mesylate
- **DRUG:** Ivonescimab
- **DRUG:** Docetaxel
- **DRUG:** Tislelizumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06868732
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-02
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 288 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06868732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06868732, "Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06868732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*